关雪娇, 李茂中, 康露, 卫小枫, 谢会, 黄芳, 宋利琼, 龚成. 2020-2023年北京市副流感病毒流行特征分析[J]. 疾病监测, 2023, 38(7): 786-791. DOI: 10.3784/jbjc.202304070153
引用本文: 关雪娇, 李茂中, 康露, 卫小枫, 谢会, 黄芳, 宋利琼, 龚成. 2020-2023年北京市副流感病毒流行特征分析[J]. 疾病监测, 2023, 38(7): 786-791. DOI: 10.3784/jbjc.202304070153
Guan Xuejiao, Li Maozhong, Kang Lu, Wei Xiaofeng, Xie Hui, Huang Fang, Song Liqiong, Gong Cheng. Epidemiology of human parainfluenza virus in Beijing, 2020−2023[J]. Disease Surveillance, 2023, 38(7): 786-791. DOI: 10.3784/jbjc.202304070153
Citation: Guan Xuejiao, Li Maozhong, Kang Lu, Wei Xiaofeng, Xie Hui, Huang Fang, Song Liqiong, Gong Cheng. Epidemiology of human parainfluenza virus in Beijing, 2020−2023[J]. Disease Surveillance, 2023, 38(7): 786-791. DOI: 10.3784/jbjc.202304070153

2020-2023年北京市副流感病毒流行特征分析

Epidemiology of human parainfluenza virus in Beijing, 2020−2023

  • 摘要:
      目的  分析2020—2023年北京市副流感病毒(HPIVs)的流行特征。
      方法  收集北京市35家哨点医院就诊的急性呼吸道感染病例的病原学标本,检测HPIV-1、HPIV-2、HPIV-3、HPIV-4和其他常见呼吸道病毒。
      结果  2020年1月至2023年2月北京市HPIVs总体阳性率为3.22%(486/15106),HPIVs阳性率在2020年最低(1.65%,70/4234),随后逐年增加,2022年阳性率达5.61%(214/3817),2023年1—2月阳性率2.54%(27/1062)。 HPIVs流行高峰在秋季。 此外,HPIVs在2022年10月的阳性率(23.05%,74/321)高于2020—2023年间的任何月份。 2020—2023年以HPIV-3流行为主(2.11%,318/15106),其次是HPIV-1(0.73%,111/15106)、HPIV-2(0.24%,36/15106)和HPIV-4(0.15%,22/15106)。 但2022年之后,HPIV-1的阳性率大幅降低,HPIV-2阳性率明显升高。HPIVs高发人群为0~5岁(8.50%,176/2070),6~17岁(4.10%,49/1195)和60岁以上(2.82%,147/5214)。 0~5岁人群易感HPIV-3重症肺炎(8.51%,12/141)。
      结论  2020—2023年北京市HPIVs流行强度在初期明显被抑制,后期逐渐回升;流行高峰被推迟,这种特征性改变,可能影响未来的HPIVs流行。

     

    Abstract:
      Objective  To understand the epidemiological characteristics of infections with human parainfluenza viruses (HPIVs) in patients with acute respiratory tract symptoms in Beijing from 2020 to 2023.
      Methods  Clinical samples of patients with acute respiratory infection were collected in 35 sentinel hospitals in Beijing and tested for HPIV-1, HPIV-2, HPIV-3, HPIV-4 and other common respiratory tract viruses.
      Results  The overall HPIV positive rate in Beijing from January 2020 to February 2023 was 3.22% (486/15106), with the lowest HPIV positive rate in 2020 (1.65%, 70/4234), followed by an increase to 5.61% (214/3817) in 2022 and 2.54% (27/1062) during January-February 2023. The annual infection peak of HPIV was in autumn. In addition, the HPIV positive rate in October 2022 (23.05%, 74/321) was higher than that in any month between 2020 and 2023. In 2020−2023 HPIV-3 was the most commonly detected (2.11%, 318/15106), followed by HPIV-1 (0.73%, 111/15106), HPIV-2 (0.24%, 36/15106) and HPIV-4 (0.15%, 22/15106). But after 2022, the positive rate of HPIV-1 decreased obviously, while the positive rate of HPIV-2 increased significantly. HPIVs were mainly detected in people aged 0-5 years (8.50%, 176/2070), 6−17 years (4.10%, 49/1195) and over 60 years (2.82%, 147/5214). Children aged 0−5 years were susceptible to severe pneumonia caused by HPIV-3 with a positive rate of 8.51% (12/141).
      Conclusion  In 2020−2023, the incidence intensity of HPIV infection was significantly suppressed in the initial phase and gradually rebounded in the later phase; the peak of HPIV infection was delayed, which might influence the incidence of HPIV infection in future.

     

/

返回文章
返回